gamal akabani, phd

Gamal Akabani, PhD.

Curriculum Vitae

SUMMARY

Basic research: I have demonstrated capacity in the basic medical sciences, biomedical

engineering, nuclear medicine imaging, nuclear oncology, radiation Monte Carlo transport,

radiation oncology, radiotherapy physics, radiobiology, PK/PD and PBPK modeling, basic

immunology, and radiopharmaceutical research. I have used in vivo models using ectopic,

orthotopic and metastatic tumor animal models to study the spatiotemporal tumor

pathophysiology and effect of therapeutics using MR Microscopy, micro-PET, GFP-based

imaging, intra-vital microscopy, FACS, microarray analysis, and immunohistochemical techniques.

My research has been focused on the development of diagnostic and therapy strategies for the

management and treatment of brain tumors using multi-target and combinatorial drugs, including

radiolabeled mAb, immuno-toxins, and small MW anti-invasive compounds, capable of modifying

the progression and eradication of invasive tumor cells including cancer stem cells.

Clinical research: I have over ten years of experience in the development and integration of

medical systems for the diagnostic and treatment of cancer. My clinical research experience

encompasses the use of single photon emission computer tomography (SPECT), positron

emission tomography (PET/CT), MRI, pharmacokinetic modeling, radiation dosimetry, small-

scale dosimetry, and morphological microdosimetry of gamma, beta and alpha particle emitting

radiolabeled mAbs and compounds for the treatment of cancer using systemic and loco-regional

delivery routes. Furthermore, I have extensive experience in the development and execution of

clinical trials with radiolabeled monoclonal antibodies for the treatment of Non-Hodgkin’s

lymphoma and brain tumors. Of relevance, I carried out the multi-center phase I, II clinical trials

of 131

I-labeled 81C6 mAb for the therapy of brain tumors, phase I, II and III clinical trials of 131

I-

labeled tositumomab mAb (BEXXAR) (Anti-CD20) for the treatment of NHL, and phase I

clinical trial of the alpha particle emitting 211

At-labeled anti-tenascin chimeric 81C6 mAb for the

treatment of recurrent brain tumors.

EDUCATION:

Curriculum Vitae - Gamal Akabani

Tuesday, July 14, 2009

Ph. D. (Medical Physics), Dept. of Nuclear Engineering, Texas A&M University. College Station,

Texas. Dissertation Title: Internal Dosimetry of Electron and Beta Particles. 1990.

Advisor: John. W. Poston, Sr. GPA: 3.8.

M.S. (Health Physics), Dept. of Nuclear Engineering, Texas A&M University. College Station,

Texas. Thesis Title: A Filter for the Compensation of the Angular Dependence of

LiF:Mg,Ti for Beta Radiation. 1987. Advisor: John. W. Poston, Sr. GPA: 3.7.

B. S. (Physics), National Autonomous University of Mexico. Mexico City. 1985. GPA: 3.8.

PROFESSIONAL RECORD:

2008 – Present Associate Professor, Department of Nuclear Engineering, Texas A&MM

University, College Station, TX 77840

2007 – 2008 Senior Staff Fellow, Medical Physicist, Food and Drug Administration,

Center for Devices and Radiological Health, Office of Device Evaluation,

Radiological Devices Branch. Rockville, Maryland.

2005 – 2206 Consultant, Medical Physicist, SAAD Specialist Hospital, Al-Khobar,

Saudi Arabia.

1996 – 2005 Assistant Research Professor of Radiology, Department of Radiology,

Duke University Medical Center, Durham, North Carolina,.

1995 – 1996 Assistant Professor of Radiation Oncology, Department of Radiation

Oncology, University of Nebraska Medical Center, Omaha, Nebraska.

1990 – 1995 Senior Research Scientist, Pacific Northwest National Laboratory, Medical

Dosimetry Section, Richland, Washington.

1989 – 1990 Instructor in Medical Physics, Dept. of Nuclear Engineering, Texas A&M

University, College Station, Texas.

CONTINUOUS EDUCATION:

Oncology and Drug Discovery:

Principles and Applications of DNA Micro-arrays. BIO-TRAC 24. Foundation for

Advanced Education in the Sciences (FAES) at the NIH, Bethesda MD, 2008.

Clinical Proteomics and Biomarker Discovery. BIO-TRAC 33. Foundation for Advanced

Education in the Sciences (FAES) at the NIH, Bethesda MD. 2008.

Nanotechnology in Medicine. BIO-TRAC 32. Foundation for Advanced Education in the

Sciences (FAES) at the NIH, Bethesda MD. 2008.

Stem Cells. BIO-TRAC 18: Foundation for Advanced Education in the Sciences (FAES)

at the NIH, Bethesda MD. 2008.

New PET Guidelines for Assessment of Response to Lymphoma Treatment. Medscape

CME. 2007.



Imaging X-rays Cause Cancer: A Call to Action for Caregivers and Patients. Medscape

CME. 2007.

Biologic Therapies in Oncology: Volume 3. Medscape CME. 2007.

Understanding Pediatric Radiation Therapy. American Association of Physicists in

Medicine (AAPM). 2007.

ASH 2006: Lymphoma and Leukemia. Medscape CME. 2006.

The Case for Cure: Promising Chemotherapy Approaches for Patients With Head and

Neck Cancer. Medscape CME. 2006.

Making Better Drugs for Children with Cancer. Institute of Medicine. 2005.

The New Oncology: Cost-effectiveness and Matchless Impact of PET-CT in Cancer

Management. 2005.

Positron Emission Tomography, University of California, Los Angeles. Ahmanson

Biological Imaging Clinic. 2004.

Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis Biological

Significanceand Clinical Relevance. Harvard Medical School, Boston, MA, 2002.

Medical Physics:

CT Simulation Tools and Technology. American Association of Physicists in Medicine

(AAPM). 2006.

Use of CT and PET in Radiation Therapy. AAPM. 2006

Auger Electron Dosimetry. AAPM. 2006.

Instrumentation for PET Imaging. AAPM. 2006.

Image Reconstruction and Image Fusion (PET/CT). AAPM. 2006.

An Improved Method for Measurement of Gamma Camera Resolution. AAPM. 2006.

Image Fusion in Nuclear Medicine - PET/CT. AAPM. 2006.

Establishing minimum performance standards, calibration intervals and optimal exposure

values for a whole breast digital unit. AAPM. 2006

A method for quantifying SPECT uniformity. AAPM. 2006.

GRANT AWARDS:

Phase II Study of 44Gy from 131

I-labeled chimeric 81C6 mAb for CNS Tumors. David A.

Reardon, MD, and G. Akabani, Ph.D. NIH R21 Grant, R21CA10578-01. 2003-2004.

Alpha particle radioimmunotherapy of primary and metastatic breast cancer. G. Akabani,

Ph.D. Duke Comprehensive Cancer Center Breast SPORE Grants. 2003-2004.

Alpha particle anti-vascular therapy of malignant glioma. The Charlotte Geyer Foundation. G.

Akabani, Ph.D. Principal Investigator. 2003-2004.

SRC on Primary and Metastatic Tumors of the CNS. Core B: Medical Nuclear Physics. G.

Akabani, Ph.D. Project Leader. NIH R01 Grant, 5 P50 NS20023. 1998-2005.

Small-Scale Dosimetry of Bone Using Histological Imaging. G. Akabani, Ph.D. Principal

Investigator. NIH R29, CA70164. 1997-2002.

Modeling of Images of the Human Body for Purposes of Radiation Dosimetry. G. Akabani,

Ph.D. Principal Investigator. Pacific Northwest Laboratory, Research and Development

Grants. 1990-1991.



Considerations of Beta and Electron Transport in Internal Dose Calculations. G. Akabani,

Ph.D. Principal Investigator. DOE. 1987-1990.

Evaluation of the UD-513A TLD Reader. G. Akabani, Principal Investigator. Panasonic Corp.

1990.

Modeling of Images of the Human Body for Applications in Nuclear Medicine and Radiation

Therapy. G. Akabani, Principal Investigator. Cray Research Supercomputer Time Grants.

1989-1990.

HONORS:

1980 First prize at the IV Cybernetics Fair. UNAM, College of Science and Humanities, Mexico

City, Mexico. 1980.

1987 IAEA. International Atomic Energy Agency Fellowship Award, 1986 – 1987.

1990 Alpha Nu Sigma Honor Society (inducted at Texas A&M University). 1990.

2005 Berson-Yalow Award to Micheal R. Zalutsky for best scientific paper at the 54th meeting

of the Society of Nuclear Medicine. Toronto, Canada. 2005.

SOCIETY MEMBERSHIPS:

American Association of Physicists in Medicine (AAPM)

IEEE Society of Medical Imaging (IEEE MI)

Society of Nuclear Medicine (SNM)

European Association of Nuclear Medicine (EANM)

Society of Molecular Imaging (SMI)

American Association for Cancer Research (AACR)

The Scientific Research Society (Sigma Xi Honor Society)

JOURNAL REVIEWER:

Journal of Nuclear Medicine (JNM)

Journals for American Association for Cancer Research (AACR)

Cancer Research,

Molecular Therapeutics,

Clinical Cancer Research

Medical Physics

Journal of Neuro-Oncology

Radiation Protection Dosimetry

SPOKEN AND WRITTEN LANGUAGES:

Spanish and Arabic

PROGRAMING LANGUAGES:

FORTRAN 77, 90, 95, C, C++, MATLAB, IDL, MATHEMATICA AND MAPLE

PEER REVIEW COMMITTEES:

NIH, SBIR and STTR, Study Section in the field of radiation oncology, 2000-2003.



NIH, Radiation Oncology and Biology, Study Section, 2003-2005.

NIH, Special Emphasis Panel in New Therapeutics, Study Section, 2004-2005.

PATENTS:

RADIATION DOSIMETRY AND BLOCKING ANTIBODIES AND METHODS AND USES

THEREFORE IN THE TREATMENT OF CANCER. International Application No.:

PCT/US2005/04188. (WO/2006/073586).

BOOKS AND CHAPTERS:

i. AC James, G Akabani, A Birchall, NS Jarvis, JK Briant and JS Durham. Absorbed

Fractions for Alpha, Electron and Beta Emission. Annex H. Human Respiratory Tract

Model for Radiological Protection. Journal of the ICRP. ICRP Publication 66. 1994.

ISBN 0-08-041154-1

ii. JR Johnson and G Akabani. Radical Production in Biological Systems. In: Radiation

Damage in DNA: Structure/Function Relationships at Early Times. Eds.: Zimbrick,

John D. Fuciarelli, Alfred F. Battelle Press, 1994. ISBN 0-935470-90-5

PUBLICATIONS:

1. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS,

Greer K, Herndon Ii JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM,

Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD. Intracerebral infusion of an

EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008.

2. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon Ii JE,

McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S,

Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot

study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Neuro Oncol. 2008.

3. Michael R. Zalutsky, David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H.

Friedman, Henry S. Friedman, James E. Herndon, II, Roger E. McLendon, Charles N.

Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy N. Rich, James J. Vredenburgh,

Annick Desjardins, Sri Guruangan, Sith Sathornsumettee, John H. Sampson, Terence Z.

Wong, Xiao-Guang Zhao, and Darell D. Bigner. Clinical Experience with α-Emitting

Astatine-211: Treatment of Recurrent Brain Tumor Patients with 211At-labeled Chimeric

81C6 Anti-Tenascin Monoclonal Antibody. J Nuc Med. In press. JNM 2007.

4. Roger E. McLendon, Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda

Cleveland, Ilkcan Cokgor, James E. Herndon II, Carol Wikstrand, Susan T. Boulton, Allan H.

Friedman, Darell D. Bigner, and Michael R. Zalutsky. Tumor Resection Cavity Administered

Iodine-131-Labeled Antitenascin 81C6 Radioimmunotherapy in Patients with Malignant

Glioma: Neuropathology Aspects. Nucl Med Biol. 2007 May;34(4):405-13. (First and second

authors have equal contribution)

5. Vemulapalli S, Metzler SD, Akabani G, Petry NA, Niehaus NJ, Liu X, Patil NH, Greer KL,

Jaszczak RJ, Coleman RE, Dong C, Goldschmidt-Clermont PJ, Chin BB. (2007). "Cell



Therapy in Murine Atherosclerosis: In Vivo Imaging with High-Resolution Helical SPECT."

Radiology 242(1): 198-207.

6. Sampson JH, Gamal Akabani, Mitchel S. Berger, R. Edward Coleman, Allan H. Friedman,

Henry S. Friedman, Kim Greer, James E. Herndon, Sandeep Kunwar, Steve Marcus, Roger E.

McLendon, Alison Paolino, Kara Penne, Neil Petry, James Provenzale, David A. Reardon,

Terence Wong, Michael R. Zalutsky, Ira Pastan, Darell D. Bigner. Phase I Study of

Intracerebral Infusion of an Epidermal Growth Factor Receptor-Targeted Toxin in Recurrent

Malignant Brain Tumors. in press.

7. Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, Bankiewicz KS.

Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled

antitenascin monoclonal antibodies. Neurosurg Focus. 2006 Apr 15;20(4):e14.

8. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE

2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ,

Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner

DD, Zalutsky MR. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody

Construct Radiolabeled with 131I and Administered into the Surgically Created Resection

Cavity of Patients with Malignant Glioma: Phase I Trial Results. J Nucl Med. 2006

Jun;47(6):912-918.

9. Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211

At-labeled

trastuzumab in human breast cancer cell lines: effects of specific activity and HER2 receptor

heterogeneity on survival fraction. Nuc Med and Biol, 2006 April, 33(3):333-347.

10. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd,

McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins

A, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD.

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal

antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors:

phase II study results. J Clin Oncol. 2006 Jan 1;24(1):115-22.

11. A. T. Yordanov, O. Pozzi, S. Carlin, G. Akabani, B. Wieland and M. R. Zalutsky. Wet

harvesting of no-carrier-added 211At from an irradiated 209Bi target for radiopharmaceutical

applications. Journal of Radioanalytical and Nuclear Chemistry. 2005, Vol. 262(3), pp: 593-

599.

12. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin

Med Res. 2005 Aug;3(3):157-65.

13. Metzler, S.D.; Jaszczak, R.J.; Patil, N.H.; Vemulapalli, S.; Akabani, G.; Chin, B.B. Molecular

imaging of small animals with a triple-head SPECT system using pinhole collimation. IEEE

Transactions on Medical Imaging, Volume 24(7) 2005:853 – 862.

14. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP,

Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN,

McLendon RE, Bigner DD, Zalutsky MR. Dosimetry and radiographic analysis in newly

diagnosed patients with malignant glioma treated with iodine-131 anti-tenascin monoclonal

antibody 81C8 therapy: A phase II clinical study. Journal of Nuclear Medicine, Vol 46 (6):

1042-51, 2005.



15. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G,

Carruthers R, Dorrens J, Zalutsky MR. An efficient targeted radiotherapy/gene therapy

strategy utilising human telomerase promoters and radioastatine and harnessing radiation-

mediated bystander effects. J Gene Med. 2004 Aug;6(8):937-47.

16. Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, Toaso B,

Anderson E, Lagoo A, Clayton S, Pegram CN, Moore JO, Gockerman JP, DeCastro C,

Gasparetto C, Chao NJ, Bigner DD. Phase 1 trial study of 131I-labeled chimeric 81C6

monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 2004

Aug 1;104(3):642-8. (First and second authors have equal contribution)

17. Boskovitz A, Akabani G, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric

81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted

radiotherapy of malignant glioma. Nucl Med Biol. 2004 Apr;31(3):345-55.

18. James AC, Birchall A, Akabani G. Comparative dosimetry of BEIR VI revisited. Radiat Prot

Dosimetry. 2004;108(1):3-26.

19. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS,

Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J,

Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R,

Yuan F, Zalutsky MR, Pastan I. Progress report of a Phase I study of the intracerebral

microinfusion of a recombinant chimeric protein composed of transforming growth factor

(TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the

treatment of malignant brain tumors. J Neurooncol. 2003 Oct;65(1):27-35.

20. S Carlin, G Akabani, MR Zalutsky. In Vitro Cytotoxicity of [211At]astatide and [131I]Iodide

to Glioma Tumor Cells Expressing the Sodium Iodide Symporter. J Nucl Med. 2003:44(11):1827-38.

21. G Akabani, S Kennel, MR Zalutsky. Microdosimetry analysis of alpha particle emitting

radiotherapeutics using histological images. J Nuc Med, 44(5):792-805, 2003.

22. G. Akabani, McLendon RE. Bigner DD. Zalutsky MR. Vascular targeted endoradiotherapy of

tumors using alpha-particle-emitting compounds: theoretical analysis. International Journal of

Radiation Oncology, Biology, Physics; 54(4):1259-75, 2002.

23. Misra UK. G. Akabani, Pizzo SV. The role of cAMP-dependent signaling in receptor-

recognized forms of alpha 2-macroglobulin-induced cellular proliferation. Journal of

Biological Chemistry. 277(39):36509-20, 2002.

24. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd,

Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV,

Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD:

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered

into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J

Clin Oncol 20: 1389–1397, 2002.

25. D. E. González Trotter, R. J. Jaszczak, J. E. Bowsher, G. Akabani, and K. L. Greer. High-

Resolution Absolute SPECT Quantitation for I-131 Distributions Used in the Treatment of

Lymphoma: A Phantom Study. IEEE Transactions on Nuclear Science 48 (3): 707-714 Part

2, 2001.



26. Cokgor I., G Akabani, H. S. Friedman, A. H. Friedman, M. R. Zalutsky, L. M. Zehngebot, J.

M. Provenzale, C. D. Guy, C. J. Wikstrand, D. D. Bigner. Long term response in a patient

with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled

antichondroitin proteoglycan sulfate Mel-14 F(ab)2: A case study. Cancer, 91(9):1809-1813,

2001.

27. Misra UK, Gawdi G, Akabani G, et al. Cadmium-induced DNA synthesis and cell

proliferation in macrophages: the role of intracellular calcium and signal transduction

mechanisms. Cell Signal 2002;14:327-340.

28. Sgouros G. Stabin M. Erdi Y. Akabani G. Kwok C. Brill AB. Wessels B. Red marrow

dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components.

Medical Physics. 27:2150-2164, 2000.

29. Cokgor I.; Akabani G.; Kuan C.-T.; Friedman H.S.; Friedman A.H.; Coleman R.E.;

McLendon R.E.; Bigner S.H.; Zhao X.-G.; Garcia-Turner A.M.; Pegram C.N.; Wikstrand

C.J.; Shafman T.D.; Herndon II J.E.; Provenzale J.M.; Zalutsky M.R.; Bigner D.D. Phase I

trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients

with newly diagnosed malignant gliomas. Journal of Clinical Oncology, 18:3862-3872, 2000.

30. I Cokgor, G Akabani, CJ Wikstrand, MR Zalutsky, HS Friedman, AH Friedman, DD Bigner.

Radiolabeled monoclonal antibodies for malignant glioma: an improvement over current

therapy?. MEDSCAPE, 2000.

31. Aurlien E. Larsen RH. Akabani G. Olsen DR. Zalutsky MR. Bruland OS. Exposure of human

osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-

irradiation: analysis of cell survival and microdosimetry. International Journal of Radiation

Biology. 76:1129-41, 2000.

32. G Akabani, I Cokgor, RE Coleman, D González Trotter, TZ Wong, HS Friedman, A Garcia-

Turner, JE Herndon II, D DeLong, RE McLendon, XG Zhao, CN Pegram, DD Bigner, MR

Zalutsky, Dosimetry and Dose-Response Relationships in Newly Diagnosed Patients with

Malignant Glioma Treated with Iodine-131 Anti-Tenascin Monoclonal Antibody 81C8

Therapy. I. J. Rad. Onc. Biol. Phys., 46, 491-499, 2000.

33. RH Larsen, KM Murud, G Akabani, P Hoff, ØS Bruland, MR Zalutsky. 211At- and 131I-

Labeled Bisphosphonates with High in vivo Statbility and Bone Accumulation. J. Nuc. Med.,

40,1197-1203, 1999.

34. RE McLendon, GE Archer, RH Larsen, G Akabani, DD Bigner, MR Zalutsky. Radiotoxicity

of systemically adminstered 211

At-labeled human/mouse chimeric monoclonal antibody: a long-

term survival study with histological analysis. I. J. Rad. Onc. Biol. Phys., 45, 491-499, 1999.

35. G Akabani, C J Reist, I Cokgor, A H Friedman, H S Friedman, R E Coleman, X.-G Zhao, D

D Bigner, M R Zalutsky. Dosimetry of I-131 labeled 81C6 Monoclonal Antibody

Administered into Surgically Created Resection Cavities in Malignant Brain Tumor Patients. J.

Nuc. Med. 40,631-8, 1999.

36. MA Morse, RE Coleman, G Akabani, N Niehaus, D Coleman, HK Lyerly. Migration of

human dendritic cells after injection in patients with metastatic malignancies. Cancer Research.

59,56-8, 1999.



37. D.D. Bigner; M.T. Brown; A.H. Friedman; R.E. Coleman; G. Akabani, H.S. Friedman; W.L.

Thorstad; R.E. McLendon; S.H. Bigner; X.G. Zhao; C.N. Pegram; C.J. Wikstrand; J.E.

Herndon 2nd; N.A. Vick; N. Paleologos; I. Cokgor; J.M. Provenzale; M.R. Zalutsky. Iodine-

131-Labeled Anti-Tenascin Monoclonal Antibody 81C6 Treatment of Patients with Recurrent

Malignant Gliomas: Phase I Trial Results. J. Clinical Oncology, Vol. 16, No 6, pp: 2202-

2212, 1998.

38. C. J. C. Marriot, W. Thorstad, G. Akabani, M. T. Brown, R. E. McLendon, M. W. Hanson

and R. E. Coleman. Locally increased uptake of fluorodeoxyglucose FDG after intracavitary

administration of Iodine-131 labeled antibody for primary brain tumors. J. Nuc. Med. 39,

1376-1380, 1998.

39. G. Akabani and M. R. Zalustky. Microdosimetry of At-211 Using Histological Images:

Application to Bone Marrow. Rad. Res. 148, 599-607, 1997.

40. R H Larsen, G Akabani, P Welsh and M R Zalutsky. The cytotoxicity and microdosimetry of 211

At-labeled chimeric monoclonal antibodies on human glioma and melanoma cells in vitro.

Rad. Res. 149, 155-162 1997.

41. G Akabani, W G Hawkins, M B Eckblade, P K Leichner. Patient Specific Dosimetry Based on

Quantitative SPECT Imaging and 3D-DFT Convolution. J. Nuc. Med. 38, 308-314, 1997.

42. P K Leichner, G Akabani, D M Colcher, K A Harrison, W G Hawkins, M B Eckblade, M A

Tempero. Patient-Specific Dosimetry of Indium-111 and Yttrium-90-Labeled Monoclonal

Antibody CC-49. J. Nuc. Med. 38, 512-516, 1997.

43. A Birchall, N S Jarvis, A C James and G Akabani. Algebraic Functions to Approximate the

Fraction of Energy Absorbed by Target Tissues in 1994 ICRP Respiratory Tract Model.

National Radiological Protection Board, U.K. NRPB-M573. 1995.

44. G Akabani. Development and Implementation of Digitized Phantoms for use in Nuclear

Medicine Procedures. Symposium in Voxel Phantom Development. National Radiological

Protection Board (NRPB), United Kingdom, 1995.

45. AC James, G Akabani, A Birchall, NS Jarvis, JK Briant and JS Durham. Absorbed Fractions

for Alpha, Electron and Beta Emission. Annex H. Human Respiratory Tract Model for

Radiological Protection. ICRP Publication 66. Annals of the ICRP. 1994.

46. HL Atkins, JS Robertson, G Akabani. MIRD Dose Estimate Report No. 17: Radiation

Absorbed Dose Estimates from Inhaled 81m

Kr Gas in Lung Imaging. Medical Internal

Radiation Dose Pamphlet No. 17, J. Nucl. Med. Vol. 34, pp. 1382-1384, 1993.

47. G Akabani. Absorbed Dose Calculations in Haversian Canals for Several Beta-emitter

Radionuclides. J. Nucl. Med. Vol. 34, pp. 1361-1366, 1993.

48. G Akabani and JW Poston Sr. Absorbed Dose Calculations to Blood and Blood Vessels for

Internally Deposited Radionuclides, J. Nucl. Med. Vol. 32, pp. 830-834, 1991.

49. G Akabani, JW Poston Sr. and WE Bolch. Estimates of Absorbed Fractions in Small Volumes

for Selected Radionuclides, J. Nucl. Med. Vol. 32, pp. 835-839, 1991.

50. G Akabani and JW Poston Sr. Reevaluation of S-values Considering Electron Transport,

Proceedings of the Fifth International Radiopharmaceutical Dosimetry Symposium, pp. 274-

283. EE Watson and AT Schlafke-Stelson, Eds. CONF-910529. 1991.



51. DM Busche, G Akabani and JW Poston Sr. An Approach to Hot Particle Dosimetry using a

Monte Carlo Transport Code, Radiation Protection Management. Vol. 8, No. 5, pp. 51-64,

1991.

52. TA Shearer, G Akabani, WE Bolch, JW Poston, Sr. A Model for Electron and Beta Energy

Deposition Within Trabecular Bone, Proceedings of the Fifth International

Radiopharmaceutical Dosimetry Symposium, pp. 290-296. EE Watson and AT Schlafke-

Stelson, Eds. CONF-910529. 1991.

53. JC Liu, G Akabani, WE Bolch and JW Poston Sr. Internal Beta Dose Calculations Using a

Point Kernel Algorithm, Proceedings of the Fifth International Radiopharmaceutical

Dosimetry Symposium, pp. 297-308. EE Watson and AT Schlafke-Stelson, Eds. CONF-

910529. 1991.

54. J. Durham, WD Reece, WE Wilson and G Akabani. VARSKIN MOD 2 and SADDE MOD 2:

Computer codes for assessing skin dose from skin contamination. US. Nuclear Regulatory

Commission. NUREG/CR, 1991.

55. G Akabani and JW Poston Sr. A Filter for the Reduction of the Angular Dependence of

LiF:Ti,Mg for Beta Radiation, Radiation Protection Management Vol. 7, No. 3, p. 69, 1989.

PRESENTATIONS:

1. Cytotoxicity of astatine 211-labeled trastuzumab in human breast cancer cell lines: effects of

specific activity and receptor heterogeneity. Akabani G, Carlin S, Welch P, Zalutsky MR.

Journal of Nuclear Medicine 46 (5)Suppl. S MAY 2005.

2. A new in-vivo landmark system for aligning histology, MRI, and PET in small animal imaging.

Thies Schroeder, Hong Yuan, James E. Bowsher, Lawrence W. Hedlund, Charles T. Wheeler,

Andrea Badea, Gamal Akabani and Mark W. Dewhirst. AACR Meeting Abstracts 2005 2005:

900-d-901.

3. (64)Cu-ATSM microPET imaging of tumor hypoxia in animal tumor models: comparison with

hypoxia immunostaining. Hong Yuan, Thies Schroeder, James E. Bowsher, Laurence W.

Hedlund, Charles T. Wheeler, Davey B. Daniel, Gamal Akabani and Mark W. Dewhirst.

AACR Meeting Abstracts 2005 2005: 1243-b-1244.

4. Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody

81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the

surgically created cystic resection cavity perimeter in the treatment of patients with newly

diagnosed primary and metastatic brain tumors. J. J. Vredenburgh, D. Reardon, G. Akabani,

A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, M. Zalutsky and D. Bigner.

ournal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June

1 Supplement), 2005: 1510

5. Phase II study of 131-iodine-labeled antitenascin murine monoclonal antibody 81C6 (M81C6)

administered to deliver a targeted dose radiation boost dose of 44 Gy to the surgically created

cystic cavity perimeter in the treatment of patients with newly diagnosed primary and

metastatic brain tumors. D. Reardon, G. Akabani, A. Friedman, H. Friedman, J. Herndon, R.

McLendon, J. Quinn, J. Rich, J. Vredenburgh, K. Penne, J. Sampson, S. Gururangan, T.

Shafman, T. Wong, J. Dowell, R. Dunn, M. Badruddoja, A. Desjardins, M. Affronti, D. Allen,



S. Jackson, K. Zeigler, S. Silverman, S. Tourt-Uhlig, R. Coleman, M. Zalutsky, and D.

Bigner; Society for Neuro-Oncology Ninth Annual Meeting, October 2004. p: 381.

6. Utilizing MRI information to estimate 18

F-FDG distributions in rat flank tumors. Bowsher,

J.E.; Hong Yuan; Hedlund, L.W.; Turkington, T.G.; Akabani, G.; Badea, A.; Kurylo, W.C.;

Wheeler, C.T.; Cofer, G.P.; Dewhirst, M.W.; Johnson, G.A.; Nuclear Science Symposium

Conference Record, 2004 IEEE Volume 4, 16-22 Oct. 2004 Page(s):2488 - 2492 Vol. 4.

7. A phase II study of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly

diagnosed patients with malignant glioma: dosimetry and radiographic analysis. Gamal

Akabani, David A Reardon, R Edward Coleman, Terence Z Wong, Scott D Metzler, James E

Bowsher, Daniel P Borboriak, James M Provenzale, Henry S Friedman, Allan H Friedman,

Roger E McLendon, Michael R Zalutsky, and Darell D Bigner. JOURNAL OF NUCLEAR

MEDICINE 46 (5)Suppl. S May 2005.

8. Clinical outcome and distribution measure of a recombinant chimeric protein composed of

transforming growth factor alpha and a mutated Pseudomonas exotoxin (TP-38) via

convection-enhanced microinfusion on a phase I study for malignant brain tumor. J. H.

Sampson, G. Akabani, G. Archer, M. Berger, A. Friedman, H. S. Friedman, S. Marcus, D.

Reardon, D. D. Bigner, I. Pastan. 39th ASCO Annual Meeting. Chicago, IL. May 31-June 3,

2003. Abstract No. 397.

9. Duke Univ Med Ctr, Durham, NC; University of California, San Francisco, San Francisco,

CA; IVAX, Miami, FL; Duke Univ Med Ctrr, Durham, NC; National Cancer Institute,

Bethesda, MD

10. Convection enhanced delivery of TP-38 immunotoxin for the therapy of brain tumors:

assessment of delivery and distribution by means of SPECT and MRI. Akabani G, Metzler S,

Reardon DA, Wong T, Bigner DD, and John H. Sampson. JOURNAL OF NUCLEAR

MEDICINE 52 (5): 454 Suppl. S MAY 2003.

11. High-resolution absolute SPECT quantitation for I-131 distributions used in the treatment of

lymphoma: a phantom study. Gonzalez Trotter, D.E.; Jaszczak, R.J.; Bowsher, J.E.; Akabani,

G.; Greer, K.L.; Nuclear Science Symposium Conference Record, 2000 IEEE Volume 3, 15-

20 Oct. 2000 Page(s):18/2 - 18/6.

12. Radioimmunotherapy of Refractory Non-Hodgkin’s Lymphoma with I-131-Labeled Chimeric

81C6 Anti-Tenascin Monoclonal Antibody: Dosimetry Study. Akabani G., Rizzieri D.,

Coleman R.E., Metzler S.D., Zalutsky M.R., and Bigner D.D. JOURNAL OF NUCLEAR

MEDICINE 52 (5): 454 Suppl. S MAY 2002.

13. Alpha particle microdosimetry for 213

Bi and 211

At. Akabani G. 3rd

alpha-Immuno-Therapy

Symposium, Deutsches Krebsforschungszentrum DKFZ, Heidelberg, Germany, 3 - 4 June

2002

14. Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL).Rizzieri

DA, Akabani G, Coleman RE, Zalutsky MR, Niedzwiecki D, Payne N, Wikstrand C, Bigner

DD. BLOOD 98 (11): 4716 Part 2 NOV 16 2001

15. Radioimmunotherapy of recurrent glioma patients using alpha-particle emitting astatine-211

labeled chimeric anti-tenascin monoclonal antibody. Zalutsky MR, Akabani G, Friedman HS,



Cokgor I, Coleman RE, Friedman AH, McLendon RE, Zhao XG, Alston KL, Bigner DD

JOURNAL OF NUCLEAR MEDICINE 42 (5): 454 Suppl. S MAY 2001

16. The treatment of recurrent patients with brain tumors treated with iodine 131 anti-tenascin

monoclonal antibody 81C6 via surgically created resection cavities: The results of a phase II

trial. Cokgor I, Akabani G, Friedman A, Coleman R, Zalutsky M, McLendon R, Bigner S,

Xiao-Guang Z, Pegram C, Wikstrand C, Herndon J, Provenzale J, Friedman H, Bigner D.

NEUROLOGY 54 (7): A33-A33 Suppl. 3 APR 11 2000

17. Microdosimetry of alpha particle emitting 211

At-labeled MAb using histological images of

malignant brain tumors. G Akabani, RE McLendon, DD Bigner and MR Zalutsky. Duke

University Medical Center, Durham NC, 27710. Society of Nuclear Medicine 46 Annual

Meeting, St. Luis, Missouri, June-4- 7.

18. Astatine-211 labeled chimeric anti-tenascin antibody: Phase I trial in brain tumor resection

cavity patients. Zalutsky MR, Akabani G, Cokgor I, Friedman HS, Coleman RE, Friedman

AH, McLendon RE, Bigner DD. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 26

(9): PS651 SEP 1999

19. Dosimetry of 131

I-labeled anti-tenascin monoclonal antibody 81C6 in newly diagnosed patient

with malignant tumors. G. Akabani, I. Cokgor, R. E. Coleman, D. González Trotter, T. Z.

Wong, H. S. Friedman, A. Garcia-Turner, J. E. Herndon II, R. E. McLendon, X.-G. Zhao, C.

N. Pegram, D. D. Bigner, M. R. Zalutsky. Proceedings of the Fourth Annual Scientific

Meeting of the Society of Neuro-Oncology. Scottsdale, AZ. Nov-18-21.

20. Worsening MR and PET findings do not necessarily indicate tumor progression in patients

with resected primary brain tumors undergoing treatment with intracavitary iodine-131-

labeled anti-tenascin monoclonal antibody. Provenzale JM, Rodriguez D, Coleman RE,

Friedman HS, Akabani G, Cokgor I. RADIOLOGY. 209P: 256 Suppl. S NOV 1998.

21. Radiation dosimetry for patients with recurrent brain tumors treated with 131

I- and 211

At-

labeled anti-tenascin monoclonal antibody 81C6. G. Akabani, C.J. Reist, I. Cokgor, A.H.

Friedman, H.S. Friedman, X-G. Zhao, R.E. Coleman, D.D. Bigner, M.R. Zalutsky.

Proceedings of the Third Annual Scientific Meeting of the Society of Neuro-Oncology. San

Francisco, CA. Nov-12-15.

22. Results of a phase I trial of patients with recurrent brain tumors and prior radiation therapy

treated with I-131-labeled antitenascin monoclonal antibody 81C6 via surgically created

resection cavities. Cokgor I, Akabani G, Brown MT, Friedman AH, Coleman RE, Friedman

HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ,

Herndon JE, Vick NA, Paleologos N, Zalutsky MR, Bigner DDNEUROLOGY 50 (4):

S52005 Suppl. 4 APR 1998

23. Results of dose finding study for compartmental delivery of radiolabeled anti-tenascin

monoclonal antibody 81C6 in patients with recurrent malignant gliomas.” J.H.Sampson, A.H.

Friedman, R.E. Coleman, G. Akabani, H.S. Friedman, N.A. Vick, N. Paleologos, I. Cokgor,

M.R. Zalutsky, D.D. Bigner. Proceedings of the Third Annual Scientific Meeting of the

Society of Neuro-Oncology. San Francisco, CA. Nov-12-15.

24. Phase I Trail of Patients with Recurrent Brain Tumors and Prior Radiation Therapy treated

with 131

I-labeled Anti-tenascin Monoclonal Antibody 81C6 via Surgically-Created Resection

Cavities.” I. Cokgor, G. Akabani, M.T. Brown, A.H. Friedman, R.E. Coleman, H.S.



Friedman, W.L. Thorstad, R.E. McLendon, S.H. Bigner, X.-G. Zhao, C.N. Pegram, C.J.

Wikstrand, J.E. Herndon, N.A. Vick, N. Paleologos, M.R. Zalutsky, and D.D. Bigner.

Proceedings of ASCO Vol. 17. P: 380a (1998).

25. I-131-LL2 (anti-CD22) radioimmunotherapy (RIT) of refractory non-Hodgkin's lymphoma

(NHL): Results of a repetitive dosing trial. Vose J, Colcher D, Bierman P, Leichner P,

Akabani G, Harrison K, Hohenstein M, Lesser S, Hammershaimb L, Goldenberg DM,

Tempero M, Armitage J. JOURNAL OF NUCLEAR MEDICINE 38 (5): 211-211 Suppl. S

MAY 1997

26. Patient dosimetry-individualized [131I] anti-B-1 Mab lymphoma radioimmunotherapy: is it

feasible in a multicenter trial?” Wahl RL; Zasadny KS; Gates VR; Akabani G; Britton K; Goris

M; Macy D; Nuttall P; SgourosG. Proc Annu Meet Am Soc Clin Oncol 1997.

27. Microdosimetry and small-scale dosimetry of At-211 in bone marrow: An analysis based on

histological imaging. Akabani G, Zalutsky MR JOURNAL OF NUCLEAR MEDICINE 38

(5): 963-963 Suppl. S MAY 1997

28. Dosimetry methods for patients with malignant CNS tumors treated with I-131 81C6 via

surgically created cystic resection cavity. Akabani G, Thorstad WL, Brown MT, Coleman RE,

Zalutsky MR, Bigner DD. JOURNAL OF NUCLEAR MEDICINE 38 (5): 395-395 Suppl. S

MAY 1997

29. Wahl RL, Zasadny KS, Gates VR, Akabani G, Britton K, Goris M, Macy D, Nutall P,

Sgouros G: Patient Dosimetry-individualized I-131 Anti B-1 MAB Lymphoma

Radioimmunotherapy: Is it feasible in a multi-center trial? 1997 ASCO meeting, Poster

session.

30. Patient specific dosimetry based on quantitative SPECT imaging and 3D-DFT convolution: A

comparison with Monte Carlo transport calculations. Akabani G, Hawkins WG, Eckblade

MB, Leichner PK JOURNAL OF NUCLEAR MEDICINE 37 (5): 347-347 Suppl. S MAY

1996

31. Patient-specific dosimetry of In-111-/Y-90-labeled monoclonal antibody CC49. Leichner PK,

Akabani G, Colcher DM, Harrison KA, Hawkins WG, BaranowskaKortelywicz J, Eckblade

M, Augustine SC, Tempero MA. JOURNAL OF NUCLEAR MEDICINE 37 (5): 350-350

Suppl. S MAY 1996

32. Therapeutic Potential of Yttrium-90 Labeled Human Monoclonal Antibody (90Y-Li-Lo-

16.88) in Patients with head and Neck Squamous Cell Cancer”. P.K. Leichner, D.Lydiatt, W.

Lydiatt, D. Colcher, S.Johansson, S. Augustine, J.Baranowska-Kortylewicz, K.A. Harrison,

G. Akabani, J.L. Klein, and M.A. Tempero. Sixth Conference on Radioimmunodetection and

Radioimmunotherapy of Cancer. Princeton, New Jersey.

33. Therapy of refractory non-Hodgkin's lymphoma (NHL) with I-131-LL2 (anti-CD22)

radioimmunotherapy (RIT): Results of a repetitive dosing trial. Vose J, Colcher D, Bierman P,

Leichner P, Akabani G, Harrison K, Hohenstein M, Lesser S, Hammershaimb L, Goldenberg

DM, Tempero M, Armitage J. BLOOD 88 (10): 2258-2258 Part 1 Suppl. 1 NOV 15 1996

34. Small-scale alpha dosimetry of red bone marrow using histological images. Akabani G,

Hawkins WG, Leichner PK JOURNAL OF NUCLEAR MEDICINE 37 (5): 1042-1042

Suppl. S MAY 1996



35. Multicellular Microdosimetry of Alpha Emitting Radionuclides Using Histological Imaging”

G. Akabani, P. K. Leichner, M. H. Schneiderman. Radiation Research Society (RRS) Annual

Meeting Chicago, IL

36. Intercomparison of Personal Dosimeters Used in U.S. Department of Energy Accelerator

Facilities” J.C. McDonald, G. Akabani, RM. Loesch, M. Höfert and C. Vaerman International

Radiation Protection Association (IRPA). Vienna, Austria

37. Localized Beta Dosimetry of Bone Marrow Using Histological Images” G. Akabani.

American Association of Physicist in Medicine (AAPM) Annual Meeting. Boston, Mass.

38. Localized Alpha Dosimetry of Red Bone Marrow Using a Two-Dimensional Monte Carlo

Code and Histological Images” G. Akabani. American Association of Physicist in Medicine

(AAPM) Annual Meeting, Boston, Mass.

39. Third Intercomparison of DOE High-Energy Neutron Personnel Dosimeters” J. C. McDonald,

G. Akabani, R. Loesch. Health Physics Society (HPS) Annual Meeting. Boston, Mass.

40. Development and Implementation of Digitized Phantoms for use in Nuclear Medicine

Procedures” G. Akabani Symposium in Voxel Phantom Development. National Radiological

Protection Board (NRPB), United Kingdom. 1995.

PROFESIONAL REFERENCES:

Upon Request.

gamal akabani, phd

Technology

positron emission tomography

jw poston sr

tenascin monoclonal antibody

repetitive dosing trial

radiolabeled monoclonal antibodies

absorbed dose calculations

recurrent brain tumors

metastatic brain tumors